

LivaNova

Health innovation that matters

At LivaNova We unite to provide hope for patients and their families through innovative medical technologies, delivering life-changing solutions in select neurological and cardiac conditions. We address providers' needs by working to improve patient quality of life, safety, and access while reducing complications, hospitalization, and cost.

LivaNova is a \$1.25B* Global Medical Technology Company



Targeting growing market segments and unmet needs



Diverse global product portfolio and pipeline



Leadership positions in Cardiopulmonary and Neuromodulation



Improving the quality of patients' lives

Our Strategic Focus


Inspired People | Impactful Innovation | Accelerated Growth | Operational Excellence

Worldwide Footprint

Headquartered in London, LivaNova has a presence in more than 100 countries worldwide. The Company employs approximately 2,900 employees.

Proforma revenues by geography based on full-year 2024 net sales:

US: 55% **EU: 18%** **ROW: 27%**



The Markets We Serve

Listed on Nasdaq stock exchange as **LIVN**

NERUOMODULATION

\$554M Revenue* | \$7B Global Market**

- ➔ **Creator of VNS Therapy™**
- ➔ **Disease State:**
 - Drug-resistant epilepsy
 - Difficult-to-treat depression
 - Obstructive sleep apnea
- ➔ **Customers:**
 - Neurologists
 - Epileptologists
 - Psychiatrists
 - Neurosurgeons
 - ENT Specialists

CARDIOPULMONARY

\$683M Revenue* | \$2.1B Global Market**

- ➔ **Market-leading positions**
- ➔ **Disease State:**
 - Coronary artery disease
 - Cogenital heart defect
 - Atrial fibrillation
 - Valvular disease
- ➔ **Customers:**
 - Perfusionists
 - Intensivists
 - Cardiac Surgeons
 - Cardiologists
 - Interventional Cardiologists

*Revenue based on full-year 2024. Numbers may not be precise due to rounding. **Global market data based on full year 2024 manufacturer revenues.

Our Core Products [Click the products below to learn more](#)

EPILEPSY*

SenTiva™

Enhanced programming features, customizable treatment and therapy management while patients live their lives

145,000+ patients treated with VNS Therapy worldwide



CARDIOPULMONARY*

Essenz Perfusion System

designed to meet the modern needs of the New Era of Perfusion

Built on a 50-year legacy of safety and reliability



CARDIOPULMONARY*

Inspire™ Oxygenator

personalized perfusion – safe, easy and flexible for all adult patient sizes

4M+ patients treated to date



XTRA™ Autotransfusion System

lowers the transfusion rates during and after cardiac surgery^{1,2}

5M+ patients treated per year



Product Pipeline*

LivaNova has a differentiated pipeline targeting medical conditions with high unmet needs:

- **Difficult-to-Treat Depression (DTD):** VNS Therapy shows a significant improvement in quality of life and function. May be protective against relapse and recurrence and may return patients to “a meaningful life.”
- **Obstructive Sleep Apnea (OSA):** Conducting a clinical trial to establish the safety and effectiveness of an implantable neurostimulation device, which, if approved, would be an alternative to CPAP.

Improving quality of life for patients worldwide